Pharma BD Deal Intelligence
AbbVie's $3.9 billion bispecific antibody collaboration with Genmab locked up epcoritamab and two other DuoBody candidates for $750 million upfront. Epcoritamab's subsequent approvals in lymphoma made this a clear win, giving AbbVie a durable oncology pipeline anchor while Genmab kept 50:50 US profit-sharing plus ex-US royalties.
The collaboration includes a $750 million upfront payment by AbbVie and will focus on the development of three of Genmab's bispecific antibodies for cancer.
AbbVie and Genmab strike a EUR 3.4 billion immuno-oncology megadeal to co-develop three bispecific antibody products including epcoritamab, with AbbVie paying…
AbbVie is paying Danish antibody specialist Genmab $750 million upfront for rights to epcoritamab and other cancer drugs, with total deal value potentially…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
CORRECTION: The originally requested Pfizer/Genmab $1.9B bispecific deal from 2022 does not exist. The landmark Genmab bispecific deal was AbbVie/Genmab, announced June 2020. AbbVie paid $750 million upfront for a broad oncology collaboration to jointly develop and commercialize three bispecific antibody candidates including epcoritamab (DuoBody-CD3xCD20), DuoHexaBody-CD37, and DuoBody-CD3x5T4. Total potential value up to $3.9 billion with development, regulatory, and sales milestones. Companies share US and Japan profits 50:50; Genmab receives 22-26% tiered royalties on ex-US/Japan sales.
80K US cases/yr · $15.0B Global NHL Market (2024)
Bispecific antibodies (CD3xCD20, CD3xBCMA) emerging as off-the-shelf alternatives to CAR-T.
AbbVie/Genmab (Epkinly), Roche (Columvi/Lunsumio), J&J, Pfizer. CAR-T (Gilead/Kite, BMS) remains competitive.
30K US cases/yr · $5.0B Global DLBCL Market (2024)
DLBCL is most common aggressive lymphoma. R-CHOP first-line. CAR-T and bispecifics transformed R/R disease.
AbbVie/Genmab (Epkinly) vs Roche (Columvi) in bispecifics. Gilead/Kite (Yescarta), BMS (Breyanzi) in CAR-T. Bispecific vs CAR-T positioning is key battleground.
15K US cases/yr · $4.0B Global FL Market (2024)
Most common indolent NHL. Generally incurable but prolonged course. Novel agents expanding R/R options.
Roche (Lunsumio), Gilead/Kite (Yescarta), AbbVie/Genmab (Epkinly) in R/R FL. Lenalidomide + rituximab backbone.
AbbVie paid $750M upfront for co-development of epcoritamab and bispecific programs.
AbbVie paid $750M upfront for three DuoBody bispecific programs including epcoritamab.
First subcutaneous bispecific T-cell engager approved. Additional FL approval 2024-2025.
FDA granted accelerated approval to Epkinly on May 19, 2023 for relapsed/refractory DLBCL after 2+ prior lines. First subcutaneous bispecific for the indication; validates AbbVie-Genmab collab.
Epkinly approved in DLBCL+FL. Full approval Nov 2025. Projected $3.94B peak sales by 2031.
Epkinly approved and launching globally. Multiple label expansions underway. Assessment of AbbVie Inc.'s $3.9B acquisition of Genmab A/S and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Genmab A/S (this deal) | 2020 | $3.9B | 81 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
| AbbVie Inc. / MedinCell S.A. | 2024 | $1.9B | 61 |
← Browse all deals · How we score deals
More: 2020 deals · AbbVie Inc. deals · Oncology deals